The American Legion, an organization of 2 million U.S. military veterans, recently passed a resolution calling on the Drug Enforcement Agency to support private medical marijuana research.
The resolution was passed during the American Legion’s National Convention, which ran Aug. 30-Sept. 1, 2016, in Cincinatti, Ohio.
The American Legion’s action comes just weeks after the DEA reasserted its classification of marijuana as a Schedule 1 drug, which means it supposedly has no medical use.
The motivation behind the resolution seems to be treatment for battlefield injuries. Early in the resolution, the text reads in part, “Over the past several years, post-traumatic stress disorder (PTSD) and traumatic brain injury (TBI) have been thrust into the forefront of the consciousness of the medical community and the general public in large part due to recent combat operations and subsequent recognition of these potentially ‘silent injuries’…”
The American Legion ends the resolution by calling on the DEA “to license privately-funded medical marijuana production operations in the United States to enable safe and efficient cannabis drug development research,” and by urging the U.S. Congress “to amend legislation to remove Marijuana from schedule I and reclassify it in a category that, at a minimum will recognize cannabis as a drug with potential medical value.”